Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis (ReBUILD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02040298|
Recruitment Status : Completed
First Posted : January 20, 2014
Results First Posted : July 15, 2021
Last Update Posted : July 15, 2021
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis, Relapsing-Remitting||Drug: Clemastine Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis|
|Study Start Date :||January 2014|
|Actual Primary Completion Date :||September 2015|
|Actual Study Completion Date :||April 2016|
Active Comparator: 3 months Clemastine, 2 months Placebo
4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months
4mg tablet twice daily
Placebo tablet twice daily
Active Comparator: 3 months Placebo , 2 months Clemastine
Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
4mg tablet twice daily
Placebo tablet twice daily
- Full Field Visual Evoked Potential (VEP) [ Time Frame: Treatment start to treatment end, up to 3 months. ]The primary objective is to evaluate the efficacy of Clemastine relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials.Visual evoked potentials (VEP) are used primarily to measure the functional integrity of the visual pathways from the retina to the visual cortex of the brain. VEP latencies were collected at Baseline, Month 1, Month 3, and Month 5.
- Tolerability of Clemastine in Multiple Sclerosis (MS) Patients [ Time Frame: Treatment start to treatment end, up to 3 months. ]Will demonstrate the tolerability of Clemastine in this population. This will include special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis.This will be assessed by administering a fatigue questionnaire called the Multidimensional Assessment of Fatigue (MAF) at all four visits throughout the study. MAF scale range is 0-50. Lower scores indicate lower levels of fatigue and higher scores indicate higher levels of fatigue.
- Myelin Water Fraction (MWF) and Magnetization Transfer Ratios (MTR) [ Time Frame: Treatment start to treatment end, up to 3 months. ]
To evaluate the efficacy of Clemastine relative to placebo in increasing magnetization transfer ratios derived from magnetic resonance imaging (MRI) of the brain during the period of exposure to active treatment.
To evaluate the efficacy of Clemastine relative to placebo at reducing radial diffusivity derived from diffusion tensor imaging as assessed by magnetic resonance imaging (MRI) during the period of exposure to active medication.
- Expanded Disability Status Scale (EDSS) Score [ Time Frame: Start of treatment to end of treatment, up to 3 months ]To evaluate the efficacy of Clemastine relative to placebo in reducing the EDSS score at 90 days compared to placebo (Group A) & at 150 days compared to day 90 (Group B). EDSS is an ordinal scale for assessing neurological impairment of MS based on a neurological examination. It consists of scores in each of seven functional systems (FS) & an ambulation score that are then combined to determine the EDSS [ranging from 0 (normal) to 10 (death due to MS)]. The FSs are the Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, & Cerebral functions. FSs & EDSS steps assessed in a standardized manner. EDSS is a widely used &accepted instrument to evaluate disability status at a given time & longitudinally, to assess disability progression in clinical studies in MS.
- Serum Creatinine Level [ Time Frame: Baseline, 1 month, 3 month, 5 month ]Blood sample will be collected at each visit to evaluate health status...
- Serum Triglyceride Level [ Time Frame: Baseline, 1 month, 3 month, 5 month ]Blood sample will be collected at each visit to evaluate health status.
- Vitamin B-12 Level [ Time Frame: Baseline, 1 month, 3 month, 5 month ]Blood sample will be collected at each visit to evaluate health status.
- Human Chorionic Gonadotropin (hCG) Level in Female Patients of Childbearing Potential [ Time Frame: Baseline, 1 month, 3 month, 5 month ]Blood and urine sample will be collected to assess pregnancy status of all female participants of child bearing potential.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02040298
|United States, California|
|UCSF Multiple Sclerosis Center|
|San Francisco, California, United States, 94518|
|Principal Investigator:||Ari J. Green, MD, MCR||University of California, San Francisco|